Oncology Letters · 2019 · 66 citations · 32 references
Life SciencesImmunologyOncologyCancer ImmunologyMolecular OncologyTumor ImmunologyCancer ImmunotherapyImmune CheckpointsImmuno-oncology BiomarkersTumor AntigensTumor-associated AntigensTumor-infiltrating LymphocytesImmune Checkpoint Ligand ExpressionPrognostic Factors AnalysisProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death-ligand 1 BiomarkerProgrammed Death-ligand 1 InhibitionReceptorsSurvival RatesT-cell Immunoreceptor Tyrosine-based Inhibitory Motif Domain
Immune checkpoints expressed on tumor cells may suppress the cytotoxicity of tumor‑infiltrating lymphocytes (TILs) via interaction with their ligands. In the present study, checkpoint proteins and ligands, including programmed death‑1 (PD‑1), programmed death ligand‑1 (PD‑L1), cluster of differentiation (CD)155 and T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) were systematically analyzed in patients with small cell lung cancer (SCLC). Furthermore their clinicopathological features and survival rates were investigated. Immunohistochemistry was performed in order to analyze the expression of PD‑L1, CD155, PD‑1 and TIGIT in 60 patients with SCLC, and survival analyses were performed using the Kaplan‑Meier method and Cox proportional hazards model. It was reported that CD155/TIGIT and PD‑L1/PD‑1 were highly expressed on tissues of surgically resected SCLC. High expression levels of PD‑L1, CD155 or PD‑L1+CD155 were significantly associated with shorter survival. However, high expression levels of PD‑1 or TIGIT exhibited no obvious association with shorter survival time. Moreover, patients with SCLC in whom PD‑L1 and CD155 levels were highly expressed had the shortest survival rate. Multivariate survival analysis revealed that highly expressed PD‑L1 [hazard ratio (HR)=2.55, 95% confidence interval (CI)=1.18‑5.51, P=0.017] and CD155 (HR=2.40, 95% CI=1.05‑5.50, P=0.038) were independent prognostic factors for overall survival (OS) time in SCLC. In addition, it was reported that TIGIT and PD‑1, the receptors of CD155 and PD‑L1, respectively, were also constitutively expressed on CD8+ TILs and tumor cells in SCLC. High expression levels of PD‑L1 and CD155 were independent prognostic factors for OS time in patients with SCLC.
32
Global cancer statistics, 2012
Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2015 · 27.4K citations · Full text
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.2K citations · Full text
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
Robert J. Johnston, Laëtitia Comps‐Agrar, Jason A. Hackney et al. · Cancer Cell · 2014 · 1.2K citations · Full text
Life Sciences, Immunology, Oncology +12